<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052701</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00023807</org_study_id>
    <nct_id>NCT01052701</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment</brief_title>
  <official_title>Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out whether abacavir (Ziagen®) lowers the levels of
      ribavirin (Ribapak®) in the body of persons taking these two drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abacavir is an anti-HIV drug that belongs to the class of nucleoside reverse transcriptase
      inhibitors. Ribavirin is a drug used to treat hepatitis C infection. Both abacavir and
      ribavirin are approved by the Food and Drug administration (FDA). The doses of abacavir and
      ribavirin used in this study are also FDA approved.Some individuals who have HIV infection
      also have hepatitis C. It is possible that they may need to take both abacavir to treat HIV
      and ribavirin to treat hepatitis C. Recent studies suggest that abacavir decreases the level
      of ribavirin in the body, in the blood and in cells named peripheral blood mononuclear cells
      (PBMC's). Thus, taking ribavirin and abacavir together could lead to treatment failure for
      hepatitis C. Therefore, it is important to understand whether ribavirin levels are affected
      when the two medications are taken together.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations</measure>
    <time_frame>Day 56</time_frame>
    <description>Ribavirin Triphosphate (RBV-TP) intracellular concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma RBV Trough Concentrations</measure>
    <time_frame>Day 56</time_frame>
    <description>Plasma RBV trough concentrations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Ribavirin plus Abacavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ribavirin plus Abacavir Administration intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribavirin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ribavirin alone administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
    <arm_group_label>Ribavirin alone</arm_group_label>
    <other_name>Ribavirin (RBV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin plus Abacavir (ABC)</intervention_name>
    <description>Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)
Plus
Daily Abacavir 300 mg orally every 12 hours</description>
    <arm_group_label>Ribavirin plus Abacavir</arm_group_label>
    <other_name>RBV + ABC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatitis C Virus (HCV) -monoinfected subjects who either successfully completed
             (defined as cured) or previously failed RBV-based therapy for hepatitis C infection,
             and are currently not receiving therapy for hepatitis C; at least 18-64 years of age.
             HCV cure is defined as a sustained undetectable viral response at 24 weeks post
             treatment.

          -  Females who are not of reproductive potential (defined as women who have been
             postmenopausal for at least 24 consecutive months or who have undergone hysterectomy,
             bilateral oophorectomy, or bilateral tubal ligation.

          -  Negative serum β- human chorionic gonadotropin (HCG)

          -  Negative HIV-1 serology documented by any licensed Enzyme-linked immunoassay (ELISA)
             test kit within 30 days prior to study entry.

          -  Positive HCV antibody documented within 30 days prior to study entry.

          -  Negative Human Leukocyte Antigen (HLA)-B*5701 test documented within 30 days prior to
             study entry.

          -  Ability and willingness of subject to provide a signed informed consent and comply
             with study requirements.

          -  All subjects must not participate in a conception process (e.g., active attempt to
             impregnate, sperm donation, in vitro fertilization). If participating in sexual
             activity that could lead to pregnancy, male subjects must take every precaution to
             avoid risk of pregnancy for their female partners by using reliable contraception
             (condom) while receiving study therapy and for 6 months following permanent
             discontinuation of study therapy. Subjects will also be instructed to counsel their
             female partners regarding fetal risk and need for appropriate contraception (e.g.,
             hormonal, barrier) so as a secondary effort to prevent pregnancy even though the
             female partners will not be study participants.

          -  Estimated creatinine clearance ≥50 mL/minute, within 30 days prior to study entry

          -  Laboratory values obtained within 30 days prior to study entry:

          -  Hgb within the normal limits as defined by the reporting laboratory

          -  Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), and alkaline
             phosphatase &gt;5 x upper limit of normal (ULN) as defined by the reporting laboratory.

          -  Direct bilirubin ≤1.5 x ULN as defined by the reporting laboratory.

          -  Follicle Stimulate Hormone (FSH) measurement elevated into the menopausal range for
             females who report being postmenopausal for at least 24 consecutive months is required
             at screening for all female subjects.

          -  Subject has not consumed alcohol in the 48 hours prior to the administration of study
             drugs.

          -  Framingham cardiovascular disease risk score &lt;10%.

        Exclusion Criteria:

          -  As determined by the investigator, a significant active or previous history of
             cardiovascular, renal, hematologic, neurologic, gastrointestinal, psychiatric,
             endocrine, or immunologic disease (s). This inclusive of chronic illnesses such as
             hypertension, coronary artery disease, arthritis, diabetes, any chronic
             gastrointestinal condition that may affect drug absorption. History of chronic or
             acute medical condition that in the opinion of the investigator would jeopardize
             safety of subjects participating in this study. Any other medical or psychological
             condition that might, in the opinion of the site investigator, interfere with
             participation in the study or put subjects at undue risk.

          -  History of anemia, hemoglobinopathy or any other cause of or tendency to hemolysis.

          -  History of RBV-induced anemia that required dose reduction or discontinuation of RBV
             therapy while receiving treatment for hepatitis C infection in the past. Patients who
             required treatment with erythropoietin or blood transfusion for the management of
             RBV-associated anemia will be excluded from participating in the study.

          -  Use of prescription or over-the-counter medications, including herbal products, within
             30 days prior to study entry that in the opinion of the investigator would preclude
             study participation.

          -  Pregnant women or men with a pregnant female partner.

          -  Breast feeding

          -  Active drug use or dependence that, in the opinion of the investigator, would
             interfere with adherence to study requirements, and/or currently receiving methadone
             replacement therapy for the treatment of substance abuse.

          -  Inability of abstaining from alcohol-containing beverages for the duration of the
             study.

          -  Hospitalization or therapy for serious illness within 30 days prior to study entry as
             judged by the investigator.

          -  Known or suspected hypersensitivity reaction to study drugs or their formulations.

          -  Participation in any investigational drug study within 30 days prior to study entry.

          -  Active or history of gout disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Andrade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Drug Development Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>February 7, 2017</results_first_submitted>
  <results_first_submitted_qc>April 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2017</results_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited through general newspaper advertisements, flyers, and referral from providers specializing in hepatitis C</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ribavirin Plus Abacavir</title>
          <description>Ribavirin plus Abacavir Administration intervention
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)
or
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)
plus
Daily Abacavir 300 mg orally every 12 hours</description>
        </group>
        <group group_id="P2">
          <title>Ribavirin Alone</title>
          <description>Ribavirin alone administration
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ribavirin Plus Abacavir</title>
          <description>Ribavirin plus Abacavir Administration intervention
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
or
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)
plus
Daily Abacavir 300 mg orally every 12 hours</description>
        </group>
        <group group_id="B2">
          <title>Ribavirin Alone</title>
          <description>Ribavirin alone administration
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
or
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="50" upper_limit="58"/>
                    <measurement group_id="B2" value="50" lower_limit="48" upper_limit="54"/>
                    <measurement group_id="B3" value="52" lower_limit="49" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations</title>
        <description>Ribavirin Triphosphate (RBV-TP) intracellular concentrations.</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ribavirin Plus Abacavir</title>
            <description>Ribavirin plus Abacavir Administration intervention
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
or
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)
plus
Daily Abacavir 300 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Ribavirin Alone</title>
            <description>Ribavirin alone administration
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations</title>
          <description>Ribavirin Triphosphate (RBV-TP) intracellular concentrations.</description>
          <units>picomoles per 10^6 cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.87" spread="12.82"/>
                    <measurement group_id="O2" value="15.93" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma RBV Trough Concentrations</title>
        <description>Plasma RBV trough concentrations.</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ribavirin Plus Abacavir</title>
            <description>Ribavirin plus Abacavir Administration intervention
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
or
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)
plus
Daily Abacavir 300 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Ribavirin Alone</title>
            <description>Ribavirin alone administration
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma RBV Trough Concentrations</title>
          <description>Plasma RBV trough concentrations.</description>
          <units>micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="1.05"/>
                    <measurement group_id="O2" value="2.60" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ribavirin Plus Abacavir</title>
          <description>Ribavirin plus Abacavir Administration intervention
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
or
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)
plus
Daily Abacavir 300 mg orally every 12 hours</description>
        </group>
        <group group_id="E2">
          <title>Ribavirin Alone</title>
          <description>Ribavirin alone administration
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>transaminitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Drug Development Unit</name_or_title>
      <organization>Johns Hopkins School of Medicine</organization>
      <phone>(410) 614-8762</phone>
      <email>ejfuchs@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

